Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2018 Filed Jan 19, 2018 01:10 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
SaleCommon Stock | 652 | $9.00 | $5,868.00 |
DisclosureSEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 6 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 01:10 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionCommon Stock | 652 | $6.67 | $4,348.84 |
DisclosureSEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 5 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 01:10 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
SaleCommon Stock | 77 | $9.00 | $693.00 |
DisclosureSEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 01:10 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionCommon Stock | 77 | $6.67 | $513.59 |
DisclosureSEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 01:10 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
SaleCommon Stock | 77 | $9.00 | $693.00 |
DisclosureSEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| January 16, 2018 Filed Jan 19, 2018 01:10 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionCommon Stock | 77 | $6.67 | $513.59 |
DisclosureSEC source: 0001061983-18-000007 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:36 UTC |
PARSHALL B LYNNEDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,714 | $3.50 Strike: $8.75 | $20,000.14 |
DisclosureSEC source: 0001061983-18-000004 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 5,714 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,714 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:37 UTC |
WIERENGA WENDALLDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,714 | $3.50 Strike: $8.75 | $20,000.14 |
DisclosureSEC source: 0001061983-18-000006 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 5,714 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,714 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:36 UTC |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,714 | $3.50 Strike: $8.75 | $20,000.14 |
DisclosureSEC source: 0001061983-18-000005 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 5,714 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,714 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:36 UTC |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,428 | $3.50 Strike: $8.75 | $40,000.29 |
DisclosureSEC source: 0001061983-18-000003 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,428 Underlying: Common Stock · 11,428 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 11,428 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:35 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,428 | $3.50 Strike: $8.75 | $40,000.29 |
DisclosureSEC source: 0001061983-18-000002 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,428 Underlying: Common Stock · 11,428 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 11,428 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:35 UTC |
GAGE L PATRICKDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,428 | $3.50 Strike: $8.75 | $75,002.29 |
DisclosureSEC source: 0001061983-18-000001 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,428 Underlying: Common Stock · 21,428 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $75,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 21,428 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 77 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · derivative · entry 8 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075 Underlying: Common Stock · 77 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 653 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · derivative · entry 7 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,343 Underlying: Common Stock · 653 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 625 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · derivative · entry 6 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Underlying: Common Stock · 625 shares Expires 2025-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionCommon Stock | 625 | $6.37 | $3,981.25 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 5 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
SaleCommon Stock | 1,800 | $13.00 | $23,400.00 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 4 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,375 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionCommon Stock | 653 | $6.67 | $4,355.51 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
SaleCommon Stock | 2,460 | $12.90 | $31,734.00 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,522 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| November 02, 2017 Filed Nov 7, 2017 01:19 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
Exercise / conversionCommon Stock | 77 | $6.67 | $513.59 |
DisclosureSEC source: 0001061983-17-000065 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 24 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 694 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 23 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694 Underlying: Common Stock · 694 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,639 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 22 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,639 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,639 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 21 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639 Underlying: Common Stock · 2,639 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 843 | $13.80 | $11,633.40 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 20 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,191 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 100 | $13.80 | $1,380.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 19 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,034 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 400 | $13.68 | $5,470.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 18 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,134 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 900 | $13.65 | $12,285.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 17 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,534 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 600 | $13.60 | $8,160.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 16 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,434 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 300 | $13.55 | $4,065.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 15 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,034 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 400 | $13.35 | $5,340.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 14 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,334 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 200 | $13.30 | $2,660.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 13 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,734 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 200 | $13.25 | $2,650.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 12 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,934 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 400 | $13.23 | $5,290.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 11 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,134 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 300 | $13.20 | $3,960.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 10 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,534 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 100 | $13.18 | $1,317.50 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 9 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,834 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 1,300 | $13.15 | $17,095.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 8 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,934 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,639 | $11.10 | $29,292.90 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 7 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 300 | $13.13 | $3,937.50 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 6 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,595 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 694 | $11.10 | $7,703.40 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 800 | $13.10 | $10,480.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,201 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,639 | $11.10 | $29,292.90 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 178 | $13.05 | $2,322.90 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,362 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 694 | $11.10 | $7,703.40 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:26 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 252 | $13.80 | $3,477.60 |
DisclosureSEC source: 0001061983-17-000063 · edgardoc.xml · nonDerivative · entry 13 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,680 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:26 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 347 | $13.70 | $4,753.90 |
DisclosureSEC source: 0001061983-17-000063 · edgardoc.xml · nonDerivative · entry 12 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,932 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:26 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 100 | $13.68 | $1,367.50 |
DisclosureSEC source: 0001061983-17-000063 · edgardoc.xml · nonDerivative · entry 11 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,279 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:26 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 1,000 | $13.65 | $13,650.00 |
DisclosureSEC source: 0001061983-17-000063 · edgardoc.xml · nonDerivative · entry 10 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,379 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:26 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 1,000 | $13.60 | $13,600.00 |
DisclosureSEC source: 0001061983-17-000063 · edgardoc.xml · nonDerivative · entry 9 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,379 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:26 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 1 | $13.58 | $13.58 |
DisclosureSEC source: 0001061983-17-000063 · edgardoc.xml · nonDerivative · entry 8 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,379 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.